Cargando…
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
BACKGROUND: Central nervous system (CNS) spreading from epithelial ovarian carcinoma (EOC) is an uncommon but increasing phenomenon. We previously reported in a small series of 11 patients a correlation between Androgen Receptor (AR) loss and localization to CNS. Aims of this study were: to confirm...
Autores principales: | Mittica, Gloria, Goia, Margherita, Gambino, Angela, Scotto, Giulia, Fonte, Mattia, Senetta, Rebecca, Aglietta, Massimo, Borella, Fulvio, Sapino, Anna, Katsaros, Dionyssios, Maggiorotto, Furio, Ghisoni, Eleonora, Giannone, Gaia, Tuninetti, Valentina, Genta, Sofia, Eusebi, Chiara, Momi, Marina, Cassoni, Paola, Valabrega, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199337/ https://www.ncbi.nlm.nih.gov/pubmed/32366278 http://dx.doi.org/10.1186/s13048-020-00655-2 |
Ejemplares similares
-
Androgen receptor status predicts development of brain metastases in ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2017) -
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
por: Ghisoni, Eleonora, et al.
Publicado: (2019) -
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
por: Ghisoni, Eleonora, et al.
Publicado: (2018) -
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019) -
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
por: Borella, Fulvio, et al.
Publicado: (2020)